Nabsys is a company.
Nabsys has raised $56.0M across 4 funding rounds.
Key people at Nabsys.
Nabsys has raised $56.0M in total across 4 funding rounds.
Nabsys has raised $56.0M in total across 4 funding rounds.
Nabsys's investors include Point Judith Capital, Stata Venture Partners.
# Nabsys: Electronic Genome Mapping Pioneer
Nabsys is a genomics company specializing in electronic genome mapping (EGM) technology for structural variant analysis.[1][4] Founded in 2005 and based in Providence, Rhode Island, the company develops platforms that enable routine, accurate, and cost-effective analysis of genomic structural variations—critical for functional genomics research, clinical diagnostics, and precision medicine.[1] In August 2024, Hitachi High-Tech acquired a majority stake in Nabsys, positioning the company as a consolidated subsidiary within a global healthcare and diagnostics conglomerate.[2]
The company's core mission centers on advancing disease understanding, increasing diagnostic yield, and improving patient outcomes through accessible genomic analysis tools.[1][3] Rather than relying on traditional DNA visualization methods, Nabsys employs solid-state nanodetection technology—combining high-sensitivity electronics, nanofluidics, and computational biology—to deliver what it describes as "unprecedented scale" genome mapping capabilities.[4] This interdisciplinary approach differentiates Nabsys in a crowded genomics market where most competitors focus on sequencing or bioinformatics platforms.
Nabsys emerged from academic research at Brown University, formed in 2007 as a merger between two university-based research projects.[7] The company's founding reflected a specific insight: genome mapping didn't require visualizing DNA directly, but rather extracting the most meaningful information through novel detection modalities.[4] Under the leadership of CEO and Founder Barrett Bready, the company navigated the complex genomics market for nearly two decades, experiencing both growth phases and challenges before its acquisition by Hitachi High-Tech.[2][6]
The company's journey included periods of significant employment (nearly 50 workers at peak operations) and strategic pivots as it refined its technology platform.[7] By 2024, Nabsys had secured $117.5 million in total funding across 13 rounds, with a most recent funding amount of $38 million, demonstrating sustained investor confidence in its technology approach.[3]
Nabsys operates at the intersection of two powerful trends: the democratization of genomic analysis and the shift toward precision medicine. As sequencing costs have plummeted, the bottleneck has shifted from generating genomic data to analyzing it accurately and affordably—particularly for structural variants, which traditional short-read sequencing struggles to detect comprehensively.[1][4]
The company's timing aligns with growing clinical demand for non-invasive diagnostic tools and the pharmaceutical industry's need for better understanding of genomic variation in drug development and patient stratification.[2] Hitachi High-Tech's acquisition signals that established diagnostics manufacturers recognize electronic genome mapping as a critical capability for next-generation molecular diagnostics platforms.[2]
Nabsys also represents a broader ecosystem shift: rather than consolidating around a single dominant sequencing technology (as happened with Illumina's market dominance), the genomics field is increasingly accommodating complementary technologies optimized for specific use cases—structural variants, long-range mapping, and cost-sensitive applications.
Nabsys stands at an inflection point. Under Hitachi High-Tech's ownership, the company has transitioned from a venture-backed startup navigating market adoption challenges to a subsidiary with access to global manufacturing and clinical distribution networks.[2] The company's stated ambition extends beyond structural variant analysis to broader applications in protein and RNA analysis, positioning electronic nanodetection as a foundational platform technology rather than a point solution.[4]
The key question ahead is whether OhmX can achieve meaningful clinical adoption and reimbursement in diagnostic workflows—a challenge that has historically limited adoption of novel genomic technologies. Hitachi High-Tech's healthcare business focus on "creating a society without fear of cancer and rare disease" suggests the parent company views Nabsys' technology as central to that vision.[2] If Nabsys can establish itself as the standard for structural variant analysis in clinical settings, it could reshape how genomic diagnostics are performed globally, moving beyond research applications into routine patient care.
Key people at Nabsys.
Nabsys has raised $56.0M across 4 funding rounds. Most recently, it raised $35.0M Series D in March 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2013 | $35.0M Series D | Point Judith Capital, Stata Venture Partners | |
| Sep 1, 2011 | $10.0M Series C | Stata Venture Partners | |
| Mar 1, 2010 | $7.0M Series B | Point Judith Capital, Stata Venture Partners | |
| May 1, 2009 | $4.0M Series A | Point Judith Capital |
